August 31, 2015: Bristol-Myers Squibb struck a deal worth up to $1.25B to acquire the rights to buy Lexington, Mass.-based Promedior Inc. and its lead product to enhance the company’s early-stage fibrosis portfolio, the company announced this morning.
August 31, 2015: Amicus inked a deal to acquire the privately-held biopharmaceutical company Scioderm in a deal worth up to $847M, the company announced this morning. The acquisition places Scioderm’s lead product candidate Zorblisa into Amicus’ rare and orphan disease pipeline.
August 31, 2015: Pfizer is looking to terminate a number of its Korea-based employees as a means to increase efficiency in its management positions. The possible terminations come at a time when the small Korean branch has consistently shown strong growth despite a slowdown elsewhere.
August 31, 2015: An unidentified source reported Friday that Baxalta is in talks to acquire Ariad. The rumors drove Ariad’s stock price up 40 percent. Baxalta, a recent spinoff of Baxter, has been fending off an acquisition bid from Dublin-based Shire since early July.